Monopar Therapeutics Inc
MNPR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$612.75M
Close$
$8.32
88.4% downside
Current Fair Value
88.4% downsideOvervalued by 88.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $612.75 Million |
|---|---|
| Enterprise Value | $560.10 Million |
| Earnings per Share | $-1.85 |
| Beta | 1.62 |
| Outstanding Shares | 8,542,450 |
Return
| Return on Equity | -2638.04% |
|---|---|
| Return on Assets | -2557.44% |
| Return on Invested Capital | -3138.12% |
Valuation & Multiples
| P/E Ratio | -30.52 |
|---|---|
| PEG | -26.19 |
| Price to Sales | - |
| Price to Book Ratio | 4.78 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.14 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 6, 2026
EPS Estimate
-$0.78
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 25, 2027
EPS Estimate
-$1.09
Consensus analyst estimateRevenue Estimate
$275,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.33%▼ 68.67% |
|---|---|
| Total Invested | $29.49M▼ 94.89% |
| Investors Holding | 23▼ 75.00% |
About Monopar Therapeutics Inc
10 employees
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validi...